68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Status:
Not yet recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients
with prostate cancer. This multicenter study is planned to be conducted in patients with
biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical
radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR
prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular
entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of:
1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients
with biochemical recurrence of elevated PSA levels after initial radical radiotherapy.